{"id":"lidofenin","rwe":[],"tags":[{"label":"lidofenin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["lidofenin"],"offLabel":[],"synonyms":["lidofenin"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"lidofenin","explanation":"Imagine your body's cells have locks on them, and lidofenin is a key that fits into one of those locks. When it binds to the lock, it can either open the lock or block it from being opened by other keys. This can affect how the cell works, but the exact way it does this is still a mystery.","oneSentence":"Lidofenin is thought to work by interacting with a specific molecular target, but its exact mechanism of action is currently unknown.","technicalDetail":"Lidofenin is a small molecule that binds to a specific protein or receptor, potentially altering its activity or expression. However, the precise molecular details of this interaction are currently unknown and require further investigation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3322","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LIDOFENIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LIDOFENIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:21:12.233803","biosimilars":[],"competitors":[],"genericName":"lidofenin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00749515","phase":"PHASE4","title":"Pilot Study for Patients With Poor Response to Deferasirox","status":"COMPLETED","sponsor":"Boston Children's Hospital","startDate":"2008-03","conditions":["Transfusion-dependent Hemachromatosis","Thalassemia Major","Sickle Cell Disease"],"enrollment":15,"completionDate":"2008-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"EK22QV7701","INN_ID":"4455","UMLSCUI":"C0064964","ChEMBL_ID":"CHEMBL1400608","KEGG_DRUG":"D04730","PUBCHEM_CID":"42963","MESH_SUPPLEMENTAL_RECORD_UI":"C049470"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"LIDOFENIN","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lidofenin is a small molecule drug of the lidofenin class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. As a result, there is limited information available on its approved indications, half-life, bioavailability, generic manufacturers, or patent status. Further research is needed to understand its clinical use and safety profile. Due to the lack of information, it is difficult to provide a comprehensive summary of lidofenin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}